Nuclera expands eProtein Discovery capabilities to enable membrane protein production

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis, digital microfluidics, and optimized additive screening, eProtein Discovery can express and purify functional, correctly folded membrane proteins, in 48 hours.

Membrane proteins play vital roles in regulating cellular processes and many are implicated in the development and progression of disease. 60% of FDA-approved drugs target membrane proteins1 yet the extraction and stabilization of these structurally complex proteins remains challenging due to their intrinsic hydrophobic nature.

Nuclera demonstrated the capabilities of eProtein Discovery to produce membrane proteins by synthesizing MsbA (a membrane transporter) and ZMPSTE24 (an integral membrane protein)2. In 24 hours, eProtein Discovery evaluated different expression and purification conditions, including assessing the effects of using nanodiscs, lipids and detergents, to identify the optimal conditions for producing soluble, stable MsbA and ZMPSTE24. Scale-up production of these membrane proteins was achieved within 48 hours, enabling rapid functional evaluation. MsbA and ZMPSTE24 generated using eProtein Discovery had high-yield, were functionally active, and compatible with cryo-Electron Microscopy (cryo-EM).

Existing eProtein Discovery users can access this new membrane protein production capability through a software update.

Membrane protein production has long been a technical challenge, often resulting in misfolded or inactive proteins. eProtein Discovery overcomes these challenges, enabling scientists to rapidly produce functional membrane proteins, accelerating drug discovery and structural biology workflows.”

Dr Toby Ost, SVP of Product Development, Nuclera

Dr Konstantinos Beis, Reader in Membrane Protein Structural Biology, Imperial College London, added: “The eProtein Discovery System is a welcome new toolkit for membrane protein production. We were commissioned via Imperial Consultants to test the protein quality in our lab - and the early results are promising.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nuclera. (2025, April 16). Nuclera expands eProtein Discovery capabilities to enable membrane protein production. News-Medical. Retrieved on April 18, 2025 from https://www.news-medical.net/news/20250416/Nuclera-expands-eProtein-Discovery-capabilities-to-enable-membrane-protein-production.aspx.

  • MLA

    Nuclera. "Nuclera expands eProtein Discovery capabilities to enable membrane protein production". News-Medical. 18 April 2025. <https://www.news-medical.net/news/20250416/Nuclera-expands-eProtein-Discovery-capabilities-to-enable-membrane-protein-production.aspx>.

  • Chicago

    Nuclera. "Nuclera expands eProtein Discovery capabilities to enable membrane protein production". News-Medical. https://www.news-medical.net/news/20250416/Nuclera-expands-eProtein-Discovery-capabilities-to-enable-membrane-protein-production.aspx. (accessed April 18, 2025).

  • Harvard

    Nuclera. 2025. Nuclera expands eProtein Discovery capabilities to enable membrane protein production. News-Medical, viewed 18 April 2025, https://www.news-medical.net/news/20250416/Nuclera-expands-eProtein-Discovery-capabilities-to-enable-membrane-protein-production.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.